Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM. Nolan-Stevaux O, et al. Among authors: bailis jm. Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290.CD-23-0984. Cancer Discov. 2024. PMID: 37861452
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Chou J, et al. Among authors: bailis jm. Cancer Res. 2023 Jan 18;83(2):301-315. doi: 10.1158/0008-5472.CAN-22-1433. Cancer Res. 2023. PMID: 36351060 Free PMC article.
CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y, Fu J, Henderson M, Lee F, Jurcak N, Henn A, Wahl J, Shao Y, Wang J, Lyman M, Funes V, Espinoza B, Zhang R, Washington I, Chen SY, Zlomke H, Wang J, Niu N, Li P, Meng F, Burns W, Friedrich M, Stienen S, Bailis JM, Zheng L. Xu Y, et al. Among authors: bailis jm. Gastroenterology. 2023 Nov;165(5):1219-1232. doi: 10.1053/j.gastro.2023.06.037. Epub 2023 Jul 26. Gastroenterology. 2023. PMID: 37507075 Free article.
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Pham E, Friedrich M, Aeffner F, Lutteropp M, Mariano NF, Deegen P, Dahlhoff C, Vogel F, Bluemel C, Harrold JM, Brandl C, Grinberg N, Rattel B, Coxon A, Bailis JM. Pham E, et al. Among authors: bailis jm. Mol Cancer Ther. 2021 Oct;20(10):1977-1987. doi: 10.1158/1535-7163.MCT-21-0236. Epub 2021 Aug 10. Mol Cancer Ther. 2021. PMID: 34376583
Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations.
Cheruiyot A, Li S, Nonavinkere Srivatsan S, Ahmed T, Chen Y, Lemacon DS, Li Y, Yang Z, Wadugu BA, Warner WA, Pruett-Miller SM, Obeng EA, Link DC, He D, Xiao F, Wang X, Bailis JM, Walter MJ, You Z. Cheruiyot A, et al. Among authors: bailis jm. Cancer Res. 2021 Sep 1;81(17):4499-4513. doi: 10.1158/0008-5472.CAN-20-4016. Epub 2021 Jul 2. Cancer Res. 2021. PMID: 34215620 Free PMC article.
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, van der Vegt B, de Vries EGE, de Groot DA, Lub-de Hooge MN. Suurs FV, et al. Among authors: bailis jm. J Nucl Med. 2021 Apr 30;62(12):1797-804. doi: 10.2967/jnumed.120.259036. Online ahead of print. J Nucl Med. 2021. PMID: 33931466 Free PMC article.
39 results